About Immatics N.V.
https://www.immatics.comImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.
CEO
Harpreet Singh
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:19.38M
Value:$190.54M
BAKER BROS. ADVISORS LP
Shares:12.09M
Value:$118.88M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:12.03M
Value:$118.26M
Summary
Showing Top 3 of 73
About Immatics N.V.
https://www.immatics.comImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.19M ▲ | $59.82M ▲ | $-50.55M ▲ | -974.46% ▲ | $-0.42 ▲ | $-47.38M ▲ |
| Q2-2025 | $4.74M ▼ | $57.86M ▲ | $-70.35M ▼ | -1.49K% ▼ | $-0.58 ▼ | $-68.08M ▼ |
| Q1-2025 | $18.58M ▼ | $53.96M ▼ | $-39.85M ▼ | -214.48% ▼ | $-0.33 ▼ | $-37.46M ▼ |
| Q4-2024 | $56.25M ▲ | $55.35M ▲ | $44.86M ▲ | 79.75% ▲ | $0.46 ▲ | $46.58M ▲ |
| Q3-2024 | $50.56M | $50.05M | $-8.57M | -16.95% | $-0.08 | $915K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $430.84M ▼ | $518.56M ▼ | $101.88M ▼ | $416.68M ▼ |
| Q2-2025 | $478.19M ▼ | $567.3M ▼ | $102.73M ▼ | $464.57M ▼ |
| Q1-2025 | $543.76M ▼ | $641.69M ▼ | $105.09M ▼ | $536.61M ▼ |
| Q4-2024 | $604.45M ▲ | $696.15M ▲ | $121.3M ▼ | $574.84M ▲ |
| Q3-2024 | $490.52M | $577.23M | $194.71M | $382.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-52.67M ▲ | $-44.7M ▼ | $122.65M ▲ | $-734K ▼ | $78.29M ▲ | $-45.78M ▼ |
| Q2-2025 | $-70.35M ▼ | $-39.05M ▼ | $64.25M ▲ | $-727K ▲ | $13.79M ▲ | $-40.61M ▼ |
| Q1-2025 | $-39.85M ▼ | $-34.21M ▲ | $46.81M ▲ | $-737K ▼ | $6.1M ▼ | $-37.34M ▲ |
| Q4-2024 | $44.86M ▲ | $-58.48M ▼ | $-47.41M ▼ | $146.36M ▲ | $47.55M ▲ | $-60.21M ▼ |
| Q3-2024 | $-8.57M | $-33.73M | $67.01M | $-753K | $31.06M | $-36.53M |
CEO
Harpreet Singh
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 6
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:19.38M
Value:$190.54M
BAKER BROS. ADVISORS LP
Shares:12.09M
Value:$118.88M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:12.03M
Value:$118.26M
Summary
Showing Top 3 of 73